Echinocandins for candidemia in adults without neutropenia.
Bennett
John E
JE
Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
D000077612:Anidulafungin; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002175:Candida / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy*; D000077336:Caspofungin; D003428:Cross Infection / Q000188:drug therapy; D054714:Echinocandins; D016469:Fungemia / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D055666:Lipopeptides; D008074:Lipoproteins / Q000627:therapeutic use; D008297:Male; D000077551:Micafungin; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009503:Neutropenia; D010456:Peptides, Cyclic / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D047071:beta-Glucans / Q000037:antagonists & inhibitors*
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D047071:beta-Glucans; C033363:beta-1,3-glucan; D000077612:Anidulafungin; D000077336:Caspofungin; D000077551:Micafungin